Jinwon Life Sciences Develops Next-Generation Biopharmaceuticals Using Nucleic Acid-Based Monoclonal Antibody Platform

Jinwon Life Sciences announced on the 10th that, as part of diversifying the delivery platform technology for nucleic acid-based antibody therapeutics under development, it published a review paper on the nucleic acid-based monoclonal antibody (mAb) therapeutic delivery platform in the journal Antibodies through collaboration with field experts.

The paper was co-authored by experts in the field, including Dr. Norbert Pardi from the University of Pennsylvania, a renowned researcher in the mRNA vaccine field; Dr. Mohamed Abdel-Mohsen, an antibody engineering expert at the Wistar Institute; and Dr. Ziyang Xu from Massachusetts General Hospital (MGH), Harvard Medical School, an authority in nucleic acid-based vaccines and therapeutics research.

Monoclonal antibody therapeutics have emerged as major immunotherapies for treating various diseases such as cancer, allergies, autoimmune diseases, neurodegenerative diseases, infectious diseases, and inflammatory disorders. However, patient accessibility is limited due to high drug prices resulting from the high development and production costs.

Based on its research and development experience in nucleic acid-based vaccines, Jinwon Life Sciences has long been conducting research to enable in vivo production of monoclonal antibodies through synthetic nucleic acid-based delivery platform technology. Through this, the company expects to meet the challenges of rapid market entry and cost reduction for monoclonal antibody therapeutics, ultimately contributing to improved patient accessibility.

Park Young-geun, CEO of Jinwon Life Sciences, stated, “Our company already possesses research and development capabilities for monoclonal antibody therapeutics using a plasmid DNA delivery system. As part of diversifying the company’s nucleic acid-based vaccine and therapeutic pipeline, we are expanding to mRNA, the next-generation modality of the monoclonal antibody therapeutic platform, through open innovation.”

He added, “We expect to contribute to enhancing patient treatment accessibility and expanding drug selection options for healthcare professionals by actively collaborating with global field experts and next-generation technology platform companies to advance and diversify core technologies of the nucleic acid-based antibody platform.”

This content was produced with the assistance of AI translation services.